Total Payments
$6,233
2023 Payments
$210.13
Companies
18
Transactions
212
Medicare Patients
1,170
Medicare Billing
$116,015
Payment Breakdown by Category
Food & Beverage$5,789 (92.9%)
Education$255.51 (4.1%)
Other$189.00 (3.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $5,789 | 196 | 92.9% |
| Education | $255.51 | 13 | 4.1% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $189.00 | 3 | 3.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Lilly USA, LLC | $1,192 | 51 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $939.14 | 30 | $0 (2023) |
| Amgen Inc. | $926.50 | 30 | $0 (2021) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $678.93 | 14 | $0 (2021) |
| SANOFI-AVENTIS U.S. LLC | $520.08 | 19 | $0 (2021) |
| Novo Nordisk Inc | $482.62 | 21 | $0 (2023) |
| Merck Sharp & Dohme Corporation | $277.40 | 12 | $0 (2018) |
| AbbVie, Inc. | $223.50 | 8 | $0 (2018) |
| Gilead Sciences, Inc. | $201.51 | 4 | $0 (2018) |
| E.R. Squibb & Sons, L.L.C. | $162.81 | 3 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2023 | $210.13 | 3 | AstraZeneca Pharmaceuticals LP ($108.47) |
| 2022 | $224.98 | 5 | Novo Nordisk Inc ($130.70) |
| 2021 | $677.39 | 28 | Amgen Inc. ($173.77) |
| 2020 | $937.75 | 35 | Amgen Inc. ($354.86) |
| 2019 | $566.77 | 20 | Amgen Inc. ($175.86) |
| 2018 | $1,491 | 48 | AstraZeneca Pharmaceuticals LP ($407.48) |
| 2017 | $2,125 | 73 | Boehringer Ingelheim Pharmaceuticals, Inc. ($397.86) |
All Payment Transactions
212 individual payment records from CMS Open Payments — Page 1 of 9
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 05/09/2023 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | Cash or cash equivalent | $81.10 | General |
| Category: Diabetes | ||||||
| 03/28/2023 | AstraZeneca Pharmaceuticals LP | LOKELMA (Drug) | Food and Beverage | In-kind items and services | $108.47 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 02/14/2023 | Novo Nordisk Inc | Rybelsus (Drug), Ozempic | Food and Beverage | In-kind items and services | $20.56 | General |
| Category: Diabetes | ||||||
| 12/13/2022 | Novo Nordisk Inc | Rybelsus (Drug) | Food and Beverage | In-kind items and services | $113.06 | General |
| Category: Diabetes | ||||||
| 12/06/2022 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $17.64 | General |
| Category: Diabetes | ||||||
| 08/23/2022 | Lilly USA, LLC | MOUNJARO (Drug) | Food and Beverage | In-kind items and services | $27.57 | General |
| Category: Diabetes | ||||||
| 06/28/2022 | Lilly USA, LLC | — | Education | In-kind items and services | $11.71 | General |
| 06/12/2022 | PFIZER INC. | GENOTROPIN (Drug) | Food and Beverage | In-kind items and services | $55.00 | General |
| Category: ENDOCRINE DISEASE | ||||||
| 12/09/2021 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $125.00 | General |
| 10/05/2021 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $21.04 | General |
| Category: DIABETES | ||||||
| 09/20/2021 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $19.13 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 08/25/2021 | Amgen Inc. | — | Education | In-kind items and services | $13.89 | General |
| 08/24/2021 | Amgen Inc. | EVENITY (Biological), Prolia | Food and Beverage | In-kind items and services | $29.54 | General |
| Category: Bone Health | ||||||
| 08/10/2021 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $18.80 | General |
| Category: DIABETES | ||||||
| 07/27/2021 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $18.90 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 07/20/2021 | Amgen Inc. | EVENITY (Biological), Prolia | Food and Beverage | In-kind items and services | $24.40 | General |
| Category: Bone Health | ||||||
| 07/13/2021 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $16.88 | General |
| Category: DIABETES | ||||||
| 06/22/2021 | Novo Nordisk Inc | Ozempic (Drug), RYBELSUS | Food and Beverage | In-kind items and services | $15.24 | General |
| Category: Diabetes | ||||||
| 06/01/2021 | Amgen Inc. | EVENITY (Biological), Prolia | Food and Beverage | In-kind items and services | $26.60 | General |
| Category: Bone Health | ||||||
| 05/25/2021 | Lilly USA, LLC | BAQSIMI (Drug) | Food and Beverage | In-kind items and services | $18.67 | General |
| Category: Diabetes | ||||||
| 05/18/2021 | Lilly USA, LLC | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $18.06 | General |
| Category: Diabetes | ||||||
| 05/11/2021 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $14.18 | General |
| Category: DIABETES | ||||||
| 04/26/2021 | Novo Nordisk Inc | Ozempic (Drug), RYBELSUS | Food and Beverage | In-kind items and services | $20.80 | General |
| Category: Diabetes | ||||||
| 04/20/2021 | Lilly USA, LLC | TRULICITY (Drug) | Food and Beverage | In-kind items and services | $21.37 | General |
| Category: Diabetes | ||||||
| 04/12/2021 | Lilly USA, LLC | LYUMJEV (Drug) | Food and Beverage | In-kind items and services | $14.66 | General |
| Category: Diabetes | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 6 | 316 | 2,460 | $76,360 | $32,444 |
| 2022 | 7 | 325 | 2,242 | $76,805 | $31,730 |
| 2021 | 7 | 300 | 1,399 | $73,920 | $32,419 |
| 2020 | 5 | 229 | 415 | $55,926 | $19,421 |
Total Patients
1,170
Total Services
6,516
Medicare Billing
$116,015
Procedure Codes
25
All Medicare Procedures & Services
25 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 116 | 234 | $52,715 | $24,978 | 47.4% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 18 | 1,920 | $7,157 | $3,319 | 46.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 15 | 15 | $4,875 | $2,128 | 43.6% |
| 83037 | Hemoglobin a1c level, by device for home use | Office | 2023 | 73 | 126 | $6,300 | $1,200 | 19.0% |
| 82962 | Blood glucose (sugar) test performed by hand-held instrument | Office | 2023 | 76 | 133 | $3,325 | $426.93 | 12.8% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 18 | 32 | $1,988 | $393.88 | 19.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 108 | 215 | $48,430 | $22,387 | 46.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 25 | 25 | $8,125 | $3,326 | 40.9% |
| J0897 | Injection, denosumab, 1 mg | Office | 2022 | 19 | 1,680 | $5,595 | $3,134 | 56.0% |
| 83037 | Hemoglobin a1c level, by device for home use | Office | 2022 | 67 | 128 | $6,400 | $1,228 | 19.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 15 | 17 | $2,788 | $837.46 | 30.0% |
| 82962 | Blood glucose (sugar) test performed by hand-held instrument | Office | 2022 | 72 | 149 | $3,725 | $482.36 | 12.9% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 19 | 28 | $1,742 | $336.26 | 19.3% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 92 | 200 | $45,500 | $21,900 | 48.1% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 32 | 32 | $10,435 | $4,757 | 45.6% |
| J0897 | Injection, denosumab, 1 mg | Office | 2021 | 12 | 900 | $7,687 | $3,950 | 51.4% |
| 83037 | Hemoglobin a1c level, by device for home use | Office | 2021 | 59 | 97 | $4,850 | $941.87 | 19.4% |
| 82962 | Blood glucose (sugar) test performed by hand-held instrument | Office | 2021 | 68 | 129 | $3,225 | $423.12 | 13.1% |
| 83036 | Hemoglobin a1c level | Office | 2021 | 25 | 26 | $1,300 | $252.46 | 19.4% |
| 96372 | Injection beneath the skin or into muscle for therapy, diagnosis, or prevention | Office | 2021 | 12 | 15 | $923.00 | $195.54 | 21.2% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 88 | 194 | $43,486 | $16,076 | 37.0% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Office | 2020 | 14 | 14 | $4,590 | $1,986 | 43.3% |
| 83036 | Hemoglobin a1c level | Office | 2020 | 44 | 67 | $3,350 | $649.62 | 19.4% |
| 83037 | Hemoglobin a1c level | Office | 2020 | 30 | 40 | $2,000 | $383.65 | 19.2% |
| 82962 | Blood glucose (sugar) test performed by hand-held instrument | Office | 2020 | 53 | 100 | $2,500 | $325.83 | 13.0% |
About Dr. Chengyu Xu, M.D
Dr. Chengyu Xu, M.D is a Internal Medicine healthcare provider based in Daly City, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/24/2009. The National Provider Identifier (NPI) number assigned to this provider is 1669600086.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Chengyu Xu, M.D has received a total of $6,233 in payments from pharmaceutical and medical device companies, with $210.13 received in 2023. These payments were reported across 212 transactions from 18 companies. The most common payment nature is "Food and Beverage" ($5,789).
As a Medicare-enrolled provider, Xu has provided services to 1,170 Medicare beneficiaries, totaling 6,516 services with total Medicare billing of $116,015. Data is available for 4 years (2020–2023), covering 25 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Diabetes & Metabolism
- Location Daly City, CA
- Active Since 06/24/2009
- Last Updated 01/04/2022
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1669600086
Products in Payments
- FARXIGA (Drug) $819.70
- JARDIANCE (Drug) $811.30
- TRULICITY (Drug) $414.49
- SOLIQUA (Drug) $360.58
- Repatha (Biological) $307.94
- EVENITY (Biological) $242.85
- Creon (Drug) $223.50
- FORTEO (Drug) $168.82
- Prolia (Biological) $161.43
- Ozempic (Drug) $154.80
- Saxenda (Drug) $142.50
- Rybelsus (Drug) $133.62
- Ultomiris (Drug) $120.35
- SCS IPGs (Device) $119.41
- MOUNJARO (Drug) $108.67
- LOKELMA (Drug) $108.47
- STEGLATRO (Drug) $107.85
- BAQSIMI (Drug) $96.45
- JANUVIA (Drug) $90.31
- SOLIQUA 100/33 (Biological) $81.49
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Daly City
Kevin Wong, M.d, M.D
Internal Medicine — Payments: $45,517
Internal Medicine $45,517
Tony Wong, M.d, M.D
Internal Medicine — Payments: $40,235
Internal Medicine $40,235
Dr. John Lai, M.d, M.D
Internal Medicine — Payments: $39,667
Internal Medicine $39,667
Dr. Alice Yan, M.d, M.D
Internal Medicine — Payments: $22,968
Internal Medicine $22,968
Damon Lee, Md, MD
Internal Medicine — Payments: $20,608
Internal Medicine $20,608
Dr. Shu May Lee, M.d, M.D
Internal Medicine — Payments: $18,620
Internal Medicine $18,620